These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 32335126)

  • 1. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 8. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Tyrosine Phosphatase Non-Receptor 11 (
    Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
    [No Abstract]   [Full Text] [Related]  

  • 11. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Seo H; Song J; Kim M; Han DW; Park HJ; Song M
    Nutrients; 2018 Dec; 11(1):. PubMed ID: 30577618
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
    Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
    Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.